A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer

Trial Profile

A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs G 305 (Primary) ; Glycopyranosyl lipid adjuvant
  • Indications Advanced breast cancer; Breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Sarcoma
  • Focus Adverse reactions
  • Sponsors Immune Design
  • Most Recent Events

    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 13 May 2015 Results published in an Immune Design media release.
    • 13 May 2015 According to an Immune Design media release, results of this trial will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top